Afatinib in NSCLC harbouring EGFR mutations

Affiliations

¹ Division of Thoracic Oncology, European Institute of Oncology, 20141 Milan Italy.
² Division of Thoracic Oncology, European Institute of Oncology, 20141 Milan Italy. Electronic address: a-passaro@hotmail.it.

Comment

Filippo de Marinis et al. Lancet Oncol. 2014 Apr.

. 2014 Apr;15(4):e148-9.

doi: 10.1016/S1470-2045(13)70402-9.

¹ Division of Thoracic Oncology, European Institute of Oncology, 20141 Milan Italy.
² Division of Thoracic Oncology, European Institute of Oncology, 20141 Milan Italy. Electronic address: a-passaro@hotmail.it.

No abstract available

Comment on

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Wu YL, et al. Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15. Lancet Oncol. 2014. PMID: 24439929 Clinical Trial.